A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
Clinical Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Routine Clinical Settings in Greece
1 other identifier
observational
180
1 country
21
Brief Summary
This study is being done to evaluate the clinical outcomes of Chronic Lymphocytic Leukemia (CLL) participants treated with venetoclax as routine standard of care in Greece. The decision to treat with venetoclax is made by the participant's physician prior to being offered enrollment in this study. The objectives of this study include determining overall response rate, assessing safety information, analyzing patient profiles and disease characteristics and participant quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2020
Longer than P75 for all trials
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2019
CompletedFirst Posted
Study publicly available on registry
November 12, 2019
CompletedStudy Start
First participant enrolled
January 13, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
CompletedJuly 17, 2025
July 1, 2025
6.5 years
November 8, 2019
July 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall Response Rate (ORR)
Defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines and includes partial response (PR), nodular partial response (nPR), complete response with incomplete bone marrow recovery (CRi), and complete response (CR).
At Month 12
Secondary Outcomes (15)
Overall Response Rate (ORR)
Up to Month 36
Complete Response (CR)
Up to Month 36
Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate
Up to Month 36
Nodule Partial Response (nPR) Rate
Up to Month 36
Partial Response (PR) Rate
Up to Month 36
- +10 more secondary outcomes
Study Arms (1)
Venetoclax Participants
Participants for whom the treating physician has decided to treat with venetoclax before enrollment in this study.
Eligibility Criteria
This study will enroll adult participants (age \>=18) with confirmed diagnosis of Relapse/Refractory Chronic Lymphocytic Leukemia being treated with venetoclax in Greece as part of routine standard of care.
You may qualify if:
- Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
- Eligible to receive venetoclax as per local label
- Physician has decided to initiate CLL treatment with venetoclax and the decision to treat is made by the physician in accordance with the local label prior to any decision to approach the participant about the study
- Participant has been fully informed verbally and in writing about the study and does not object to their data being processed or subjected to data quality control
You may not qualify if:
- Prescribed or treated with venetoclax outside of marketing authorization
- Currently participating in, or previously participated within 30 days prior to venetoclax start, in any other interventional clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (21)
Henry Dunnant Hospital Center /ID# 241682
Athens, Attica, 11526, Greece
General Hospital of Athens Gennimatas /ID# 212917
Athens, Attica, 11527, Greece
General Hospital of Athens Laiko /ID# 212902
Athens, Attica, 11527, Greece
General Hospital of Athens Laiko /ID# 230222
Athens, Attica, 11527, Greece
University General Hospital Attikon /ID# 212915
Athens, Attica, 12462, Greece
Metropolitan General /ID# 212934
Cholargós, Attica, 15562, Greece
Iatriko Kentro Athinon /ID# 241689
Marousi, Attica, 15125, Greece
Iatriko Kentro Athinon /ID# 241690
Marousi, Attica, 15125, Greece
Metropolitan Hospital /ID# 241687
Piraeus, Attica, 18547, Greece
General Hospital of Chania "Agios Georgios" /ID# 241685
Chania, Chania, 73300, Greece
University General Hospital of Heraklion PA.G.N.I /ID# 212916
Heraklion, Crete, 71500, Greece
University General Hospital of Ioannina /ID# 212936
Ioannina, Ioannina, 45500, Greece
Reg Gen Univ Hosp Larissa /ID# 213708
Larissa, Larisa, 41110, Greece
Theageneio Anticancer Hospital /ID# 212933
Thessaloniki, Thessaloniki, 54639, Greece
General Hospital of Thessaloniki George Papanikolaou /ID# 213709
Thessaloniki, Thessaloniki, 57010, Greece
General University Hospital of Alexandroupolis /ID# 212927
Alexandroupoli, 68100, Greece
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 212929
Athens, 10676, Greece
General Hospital of Patras Agios Andreas /ID# 213711
Pátrai, 26335, Greece
University Gen Hosp of Patra /ID# 212914
Pátrai, 26504, Greece
METAXA Cancer Hospital of Piraeus /ID# 212918
Piraeus, 18737, Greece
Papageorgiou General Hospital /ID# 213710
Thessaloniki, 56429, Greece
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2019
First Posted
November 12, 2019
Study Start
January 13, 2020
Primary Completion
June 30, 2026
Study Completion
June 30, 2026
Last Updated
July 17, 2025
Record last verified: 2025-07